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Abstract Phospholipase D1 and D2 (PLD1, PLD2) both have
PX and PH domains in their N-terminal regions with these
inositol lipid binding domains playing key roles in regulating
PLD activity and localisation. The activity of PLD1 is also
regulated by protein kinase C and members of the Rho and
Arf families of GTPases. Each of these proteins binds to unique
sites; however, there appears to be little in vitro discrimination
between individual family members. In agonist-stimulated cells,
however, there is speci¢city, with, for example in RBL-2H3
cells, antigen stimulating the activation of PLD1 by association
with Arf6, Rac1 and protein kinase CK. PLD2 appears to be
less directly regulated by GTPases and rather is primarily con-
trolled through interaction with phosphatidylinositol 4-phos-
phate 5-kinase that generates the activating phosphatidylinositol
4,5-bisphosphate.
4 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
In most cell types a range of growth factors, hormones,
cytokines and other agonists stimulate phospholipase D
(PLD) catalysed phosphatidylcholine hydrolysis to generate
phosphatidic acid (PtdOH) as the lipid product [1]. PtdOH
apparently signals by interacting with speci¢c binding do-
mains in target proteins, e.g. PDE-4A1 [2], PP1 [3], thereby
leading to the stimulation of physiological responses. These
include the modulation of membrane tra⁄cking, e.g. exocyto-
sis [4] and endocytosis [5], and reorganisation of the actin
cytoskeleton [6,7]. Two mammalian PLD genes have been
identi¢ed, PLD1 and PLD2, each of which is expressed as
two splice variants. Both isoforms have PX and PH domains
and four conserved PLD signature domains. A catalytic
HxKxxxxD triad is found within both domains I and IV
with an additional GSANIN found in domain IV within
which the S has been shown to be essential for catalysis [1].
Despite the linkage between receptor activation and the stim-
ulation of PLD being recognised for more than 10 years, the
mechanism is incompletely de¢ned.
2. Activation by protein kinase C
PLD activation is frequently concomitant with the stimula-
tion of phospholipase C activity in stimulated cells. A poten-
tial linkage between these two enzymes can be made since
inhibition of protein kinase C, an enzyme downstream of
phospholipase C, blocks the stimulation of PLD activity [8].
The mechanism of PLD activation by protein kinase C is
however unclear. The e¡ects of protein kinase C inhibitors
suggested that PLD phosphorylation may be the mechanism
of activation, however whilst detectable [9], phosphorylation
in vitro is without signi¢cant e¡ect upon activity. Further-
more, whilst the regulatory domain of protein kinase C has
been shown to directly interact with PLD, this interaction is
independent of kinase activity as the stimulation of PLD ac-
tivity in vitro occurs in the absence of ATP. Consistent with
this, a truncated protein kinase C devoid of the catalytic do-
main was found to be capable of activating PLD [10]. Muta-
tion studies have now identi¢ed a region in PLD1 apparently
N-terminal to the PX domain where protein kinase C interacts
[11], this site thus forms one part of a triad of membrane
attachment motifs together with the PH and PX domains
(see below). This unique means of activation cannot however
fully explain the mechanism of activation of PLD by protein
kinase C, since kinase inhibitors suppress agonist-stimulated
PLD activity in most cell types. The most likely explanation is
that protein kinase C may be e¡ecting the activation of other
PLD regulators, or regulating the formation of a multi-com-
ponent regulatory complex.
3. Activation by inositol phospholipids
In addition to the protein kinase C binding motif, the N-
terminal region of both PLD1 and 2 contains the PX and PH
domains. The PH domain of PLD is selective for bisphos-
phorylated inositides having a vicinal pair of phosphates,
i.e. PtdIns(4,5)P2 and PtdIns(3,4)P2 [12]. PtdIns(3,4,5)P3 is a
weak activator of the puri¢ed enzyme, however it has a more
signi¢cant activating e¡ect in partly puri¢ed preparations. In
surface plasmon resonance experiments there was only limited
binding of PtdIns(3,4,5)P3 to the intact phospholipase and
none to the isolated PH domain, in contrast to the binding
of PtdIns(4,5)P2. Whilst the PH domain is clearly a major
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PtdIns(4,5)P2 binding regulatory domain, other studies have
provided evidence for an additional PtdIns(4,5)P2 binding do-
main which is also apparently essential for activity [13]. Bind-
ing of PtdIns(4,5)P2 to the PH domain of PLD has two func-
tions, ¢rstly mutation reduces or inhibits activation, but
secondly complete removal of the domain both ablates activ-
ity and prevents membrane association [12]. Deletion of the
N-terminus of PLD1, including the PX domain and the pro-
tein kinase C binding site as well as the PH domain, did not
decrease PLD activity. Indeed the N-terminal deletion in-
creased activity and did not prevent membrane association,
however whether the mutated enzyme localised to and trans-
located between the same membranes as the wild type protein
was not determined. It is therefore possible that deletion of
this region a¡ects in vivo regulation of the enzyme by local-
isation (see below).
The surface plasmon resonance studies showed that PLD
also bound PtdIns(3)P, but that the binding was not within
the PH domain [12]. Studies with VAM-7, p40 PHOX and
SNX3 [14] have demonstrated that the PX domain binds
PtdIns(3)P, thus it is probable that the PLD PX domain is
also a PtdIns(3)P binding motif. As observed with the other
PX domain containing proteins, the motif appears to be im-
portant in the endosomal localisation of PLD1 in particular.
The direct evidence of lipid speci¢city and function of the PX
domain in PLD remains to be provided, nevertheless there
would appear to be a complex relationship between the PH
and PX domains in PLD regulation by inositol phospholipids
with an additional indirect e¡ect upon the protein kinase C
binding domain. This relationship is probably partly re£ected
in the control of PLD’s intracellular localisation and therefore
its interaction with its regulators (see below).
4. Small GTPases and PLD activation
Whilst PtdIns(3,4,5)P3 does not bind to PLD and does not
activate the enzyme in vitro, there is clear evidence from in-
hibitor studies for a role for PI-3-kinase activation in control-
ling PLD [15]. These results pointed to mechanisms of PLD
activation following cell surface receptor occupation proceed-
ing indirectly for example via PtdIns(3,4,5)P3-regulated pro-
teins. The demonstration that PLD activity in broken cells
required GTP led to the identi¢cation of two families of small
GTPases as regulators of PLD1, ¢rstly the Arf family [16,17]
and subsequently members of the Rho family of proteins
(Rho, Rac, Cdc42) [18]. Both families were identi¢ed as direct
activators and have each been shown by surface plasmon
resonance to bind to PLD1a [19]. Whilst no Arf binding site
has been identi¢ed, Rho family proteins appear to bind to
PLD1 between amino acids 984 and 1000 in human and rat
PLD1 [20] and protein kinase C appears to bind between
amino acids 61 and 70. Other GTPases such as Ral have
subsequently been proposed to regulate PLD activity, how-
ever the control by this protein is more complex since it ap-
pears to be cooperative with Arf and apparently doesn’t re-
quire GTP loading of the Ral [21]. The importance of PI-3-
kinase in this activation of Arf and Rho proteins is suggested
by the identi¢cation of exchange factors such as Tiam-1 [22]
and the cytohesins [23] whose activity is controlled by
PtdIns(3,4,5)P3-dependent PH domains.
The Rho and Arf families both comprise multiple members
each having di¡erent functions, surprisingly each is capable of
activating PLD1, with only small di¡erences, in particular a
reduced e¡ect of Cdc42, between the abilities of the individual
members of both these GTPase families [24,25]. Further,
transfection experiments have shown that activated Rho,
Rac and Cdc42 can each activate PLD1 [1]. Nevertheless,
the distinct physiological functions of the GTPases raise ques-
tions about the speci¢city of PLD activation. Thus we ad-
dressed the interaction of PLD1 with wild type GTPases in
the RBL-2H3 model mast cell under control and antigen-
stimulated conditions. In this cell line we and others have
previously demonstrated an important role for PLD in the
regulation of antigen-stimulated secretion of the contents of
the specialised secretory lysosomes [4,26]. Incubation of the
cells with a primary, but not a secondary or tertiary alcohol
inhibited stimulated secretion without inhibiting the translo-
cation of PLD1, apparently associated with the vesicles to the
plasma membrane. This suggested that PLD1 was activated at
the plasma membrane in response to cellular stimulation.
Antigen stimulation of RBL-2H3 cells activates the syk ty-
rosine kinase, phospholipase CQ and PI-3-kinase in addition
to PLD, thus pathways involved in the control of a number of
PLD regulators are also activated. We adopted a confocal
microscopy approach to examine the association of PLD1
with potential regulatory molecules in the RBL-2H3 cells.
Where possible we made use of suitable speci¢c antibodies
to detect the localisation of the endogenous proteins, or if
necessary we examined the localisation of HA- or GFP-tagged
transfected proteins, in the latter experiments care was taken
to ensure the lowest possible level of expression of the exog-
enous proteins. In the resting cell PLD1b exhibited a punctate
presumably vesicular localisation which corresponded to
markers of the secretory lysosome, there was minimal colo-
calisation with any potential regulator. Following antigen
stimulation, PLD1b translocated to the plasma membrane
where it selectively colocalised with regulatory molecules, i.e.
Arf6 but not Arf1, Rac1 but not RhoA or Cdc42, and protein
kinase CK [19]. Concomitant with this colocalisation PLD
activity was stimulated.
These data raise questions concerning the previously re-
ported activation of PLD by other Arf and Rho proteins,
the explanation for this apparent contradiction may relate
to the plethora of cellular functions assigned to PLD. PLD
activity has been suggested to play an important role in the
fragmentation and reassembly of the Golgi apparatus in rat
liver with a pool of PLD1 being associated with Golgi mem-
branes [27], indeed we have recently detected colocalisation of
PLD1b and Arf1 in the Golgi of Cos1 cells [2]. A number of
studies have suggested that PLD is found in the Golgi, though
this has been disputed, see [28] for discussion. However, in-
volvement of PLD in processes as distinct as GLUT4 glucose
transporter translocation [29,30], EGF [5] and FcQRI receptor
internalisation [31], hepatic very low density lipoprotein as-
sembly [32] and the release of nascent secretory vesicles
from the trans Golgi network [33] suggests that the enzyme
plays a number of roles in tra⁄cking events. These processes
have also been variously suggested to involve Arf1, Arf6,
RhoA and B and Rac1. There is also extensive evidence
that PLD activation plays an important role in control of
the actin cytoskeleton. A number of studies have shown
that activation of PLD stimulates the formation of actin stress
¢bres in endothelial [7] and ¢broblast cells [6], and using cat-
alytically inactive constructs it has been demonstrated that
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this may be a PLD1-mediated event [34]. Association of PLD
with the actin cytoskeleton is further suggested by the impor-
tance of the Rho proteins and Arf6 in controlling actin rear-
rangements and in cell movement, for example a critical role
for Arf6 and PLD activity in wound healing has recently been
demonstrated [35]. Furthermore, actin has been shown to bind
to PLD2 with an inhibitory e¡ect upon phospholipase activ-
ity, and at least in vitro this is reversed by Arf1 [36]. However
in vivo, a relationship between Arf6, rather than Arf1 and
PLD2 together with PtdIns4-P-5-kinase IK has been suggested
[37].
The association between PLD2 and PtdIns4-P-5-kinase IK
has provided a mechanism for regulation of this PLD isoform.
Whilst both PLD1 and PLD2 bind PtdIns4-P-5-kinase IK, it is
only the activity of PLD2 that is increased when the two are
co-expressed; a catalytically inactive PtdIns4-P-5-kinase IK
also inhibits PLD2 activation [38]. Thus, it appears that
PLD2 activity is regulated by PtdIns(4,5)P2 availability.
PtdIns4-P-5-kinase IK activity is regulated by both PtdOH
and Arf6, this provides a potential link between PLD1 and
PLD2 activity and points to the cooperative roles of the two
enzymes particularly in controlling cell shape change, an event
in which PtdIns(4,5)P2 is heavily implicated.
Whether each of these regulatory functions operates in the
same cell under the activation of a single agonist is unknown,
however in the RBL-2H3 model cell, antigen stimulates both
the secretion of the contents of the secretory lysosome and the
spreading and migration of the cell. This sequence of events
operates in a number of stimulated haematopoietic cells, con-
sequently there may be a coordinated regulation of the two
PLDs in a number of cellular processes, the control of which
will involve distinct small GTPases and inositol phospholip-
ids.
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